CompletedEarly Phase 1NCT00874861
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
Studying Oligoastrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ian F. Pollack, M.D.
- Principal Investigator
- Frank Lieberman, MD, M.DUniversity of Pittsburgh Medical Center
- Intervention
- Peptide vaccine + Poly-ICLC(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2013
Study locations (1)
- UPMC Hillman Cancer Center (University of Pittsburgh Cancer Institute), Pittsburgh, Pennsylvania, United States
Collaborators
Musella Foundation · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00874861 on ClinicalTrials.gov